Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
529 Leser
Artikel bewerten:
(2)

Larose Ventures Ltd.: Larose Ventures Announces Completion of Amalgamation with 1282454 B.C. Ltd.

VANCOUVER, BC / ACCESSWIRE / February 19, 2021 / Larose Ventures Ltd. (the "Company" or "Larose"), is pleased to announce that further to its news release dated January 22, 2021, the Company has completed its previously announced amalgamation with 1282454 B.C. Ltd. ("1282454 BC") (the "Amalgamation").

Pursuant to the terms of the Amalgamation, Larose and 1282454 BC have amalgamated and continued as one company ("Amalco") pursuant to the provisions of Section 269 of the Business Corporations Act (British Columbia) ("BCBCA"). Upon completion of the Amalgamation, all Larose common shares outstanding immediately prior to the Amalgamation were exchanged for new Amalco Class A redeemable preferred shares on a one for one basis; all 2,000,000 common shares of 1282454 BC outstanding immediately prior to the Amalgamation were exchanged for new Amalco common shares on a one for one basis; and all Larose stock options currently outstanding were cancelled. Immediately following the Amalgamation, Amalco has redeemed the outstanding Class A redeemable preferred shares at a price of $0.0075 per share.

The Amalgamation was approved by over 98% of the Company's shareholders at its annual general and special meeting on February 16, 2021.

The name of the amalgamated entity remains "Larose Ventures Ltd.".

Upon closing of the Amalgamation, Michael Lerner, Harvey McKenzie and Neil Novak have been appointed as directors of the Company, replacing Scott Ackerman, Rick Cox and Brent Ackerman, who have resigned as directors of the Company. In addition, Michael Lerner has been appointed President and Chief Executive Officer and Balu Gopalakrishnan has been appointed Chief Financial Officer, replacing Scott Ackerman who has resigned as an officer of the Company. The Company wishes to thank the former directors and officers for their service to the Company.

As a result of the Amalgamation, each of Jennifer Goldman ("Goldman") of Ontario, and BC based L5 Capital Inc. ("L5") has ownership and control over 1,000,000 common shares at a cost of $0.125 per share. Neither the Company, nor to the knowledge of the Company after reasonable enquiry, Goldman or L5, have knowledge of any material information concerning the Company or its securities which has not been generally disclosed.

Goldman and L5 have individually acquired the above-noted common securities for investment purposes. Independently, Goldman and L5 may in the future take such actions in respect of its holdings in the Company as they may deem appropriate in light of the circumstances then existing, including the purchase of additional securities of the Company through open market purchases or privately negotiated transactions or the sale of all or a portion of their individual holdings in the open market or in privately negotiated transactions to one or more purchasers, subject in each case to applicable securities law.

This news release is issued pursuant to National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, which also requires a report to be filed with the applicable securities commissions or similar regulatory authorities in Canada, which report will contain additional information with respect to the foregoing matters (the "Early Warning Report"). A copy of the Early Warning Reports may be obtained by contacting the Company, and will also be filed on SEDAR under the Company's profile at www.sedar.com.

For more information, please contact the Company at (416) 710-4906 or email: mlerner10@gmail.com.

On Behalf of the Board of Directors of Larose Ventures Ltd. Michael Lerner
Director

This news release includes forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward- looking statements.

SOURCE: Larose Ventures Ltd.



View source version on accesswire.com:
https://www.accesswire.com/630776/Larose-Ventures-Announces-Completion-of-Amalgamation-with-1282454-BC-Ltd

© 2021 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.